An Effective and Chemotherapy-Free Strategy of All-Trans Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia in All Risk Groups (APL15 Trial)

Investigators performed a randomized multi-center non-inferiority phase III study to compare the efficacy of all-trans retinoic acid (ATRA)-arsenic trioxide (ATO) and ATRA-ATO plus chemotherapy in newly diagnosed all-risk acute promyelocytic leukemia patients.
[Blood Cancer Journal]
Full Article

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News